

BioGaia signs exclusive agreement for oral health products in Mexico

BioGaia has today signed an exclusive agreement with Silanes for the rights to sell BioGaia's oral health lozenges in Mexico. The launch is planned to take place during 2015.

Silanes is one of the leading pharmaceutical companies in Mexico with more than 70 years of experience and worldwide presence. The company is focused on medical prescription products for chronic diseases such as diabetes and metabolic syndrome. Silanes is part of Grupo Silanes with operations centered around two core strategies - innovation and globalization.

Diabetics have frequent and serious oral health problems and they are therefore a very important target group for BioGaia's oral health lozenges. Silanes will market them under its diabetes care brand ProBucal-D. The product contains the patented and well-documented probiotic strain *Lactobacillus reuteri* Prodentis. Today the lozenges are sold in more than 20 countries.

It is estimated that more than 6.4 million Mexicans, or almost a sixth of the adult population, suffer from diabetes, according to the 2012 Mexican National Health and Nutrition Survey (ENSANUT), carried out by the Mexican Ministry of Health.

"Silanes is committed to bringing new knowledge to diabetes doctors in Mexico. BioGaia's oral health products are backed by an impressive amount of clinical data and will support Silanes' portfolio of products for the treatment and prevention of diabetes and associated conditions", says Javier Luna, Director, Silanes Nutrition Health.

"Mexico is the country with the sixth highest number of diabetics in the world and diabetes is often associated with oral diseases. With a strong local partner we hope for a successful launch of BioGaia's oral health products in Mexico", says Peter Rothschild, President, BioGaia.

For additional information please contact

Peter Rothschild, President, telephone: +46 8 555 293 00

Latest press releases from BioGaia

2015-03-09	BioGaia's oral health probiotic effective in patients with dental implants
2015-02-23	BioGaia subsidiary Infant Bacterial Therapeutics get Orphan Drug Designation in Europe
2015-02-12	BioGaia AB – Year-end report 2014

BioGaia has published this information in accordance with the Swedish Securities Market Act. The information was issued for publication on 23 March 2015, 01:00 pm CET.

BioGaia is a healthcare company that develops, markets and sells probiotic products with documented health benefits. The products are primarily based on the lactic acid bacterium *Lactobacillus reuteri* which has probiotic, health-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap list of the NASDAQ OMX Nordic Exchange Stockholm. www.biogaia.com